Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.

Duran GE, Derdau V, Weitz D, Philippe N, Blankenstein J, Atzrodt J, Sémiond D, Gianolio DA, Macé S, Sikic BI.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1095-1103. doi: 10.1007/s00280-018-3572-1. Epub 2018 Apr 19.

PMID:
29675746
2.

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.

Duran GE, Wang YC, Moisan F, Francisco EB, Sikic BI.

Br J Cancer. 2017 May 9;116(10):1318-1328. doi: 10.1038/bjc.2017.102. Epub 2017 Apr 11.

3.

The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.

Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI.

Mol Oncol. 2015 Oct;9(8):1678-93. doi: 10.1016/j.molonc.2015.04.015. Epub 2015 May 16.

4.

Mechanisms of resistance to cabazitaxel.

Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI.

Mol Cancer Ther. 2015 Jan;14(1):193-201. doi: 10.1158/1535-7163.MCT-14-0155. Epub 2014 Nov 21.

5.

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI.

Mol Oncol. 2014 Oct;8(7):1231-9. doi: 10.1016/j.molonc.2014.03.016. Epub 2014 Apr 18.

6.

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.

Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI.

Mol Cancer Ther. 2010 Nov;9(11):2970-81. doi: 10.1158/1535-7163.MCT-10-0780. Epub 2010 Nov 9.

7.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

8.

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI.

Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23.

PMID:
19108889
9.

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI.

Genes Chromosomes Cancer. 2006 Apr;45(4):365-74.

PMID:
16382445
10.

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.

Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI.

J Clin Oncol. 2006 Jan 10;24(2):274-87. Epub 2005 Dec 19.

PMID:
16365179
11.

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17763-8. Epub 2005 Nov 23.

12.

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.

Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI.

Cancer Res. 2005 Oct 15;65(20):9388-97.

13.

Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.

Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen KG, Derry WB, Wilson L, Jordan MA, Sikic BI.

Bull Cancer. 2004 May;91(5):E81-112.

14.

Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.

Lacayo NJ, Duran GE, Sikic BI.

J Exp Ther Oncol. 2003 May-Jun;3(3):127-35.

PMID:
14641819
15.

Gene expression patterns in ovarian carcinomas.

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI.

Mol Biol Cell. 2003 Nov;14(11):4376-86. Epub 2003 Sep 5.

16.

Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.

Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI.

Mol Cancer Ther. 2002 Jan;1(3):215-25.

17.

Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma.

Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI.

Genes Chromosomes Cancer. 2002 Aug;34(4):372-83.

PMID:
12112526
18.

MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.

Chen GK, Durán GE, Mangili A, Beketic-Oreskovic L, Sikic BI.

Br J Cancer. 2000 Oct;83(7):892-8.

19.
20.

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.

Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):203-9.

PMID:
9803961
21.

Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.

Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI.

J Biol Chem. 1997 Feb 28;272(9):5974-82.

22.

Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia.

Kühl JS, Krajewski S, Durán GE, Reed JC, Sikic BI.

Br J Cancer. 1997;75(2):268-74.

23.

Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI.

Cancer Res. 1996 Mar 1;56(5):1091-7.

24.

Differential expression of tubulin isotypes during the cell cycle.

Dumontet C, Durán GE, Steger KA, Murphy GL, Sussman HH, Sikic BI.

Cell Motil Cytoskeleton. 1996;35(1):49-58.

PMID:
8874965
25.

Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.

Duran GE, Lau DH, Lewis AD, Kühl JS, Bämmler TK, Sikic BI.

Cancer Chemother Pharmacol. 1996;38(3):210-6.

PMID:
8646794
26.

Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

Beketic-Oreskovic L, Durán GE, Chen KG, Dumontet C, Sikic BI.

J Natl Cancer Inst. 1995 Nov 1;87(21):1593-602.

PMID:
7563202
27.

Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance.

Jaffrézou JP, Chen KG, Durán GE, Muller C, Bordier C, Laurent G, Sikic BI, Levade T.

Biochim Biophys Acta. 1995 Apr 6;1266(1):1-8.

28.

Volume-activated chloride current is not related to P-glycoprotein overexpression.

Dong Y, Chen KG, Durán GE, Kouyama K, Chao AC, Sikic BI, Gollapudi SV, Gupta S, Gardner P.

Cancer Res. 1994 Oct 1;54(19):5029-32.

29.
30.

Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.

Jaffrézou JP, Chen KG, Durán GE, Kühl JS, Sikic BI.

J Natl Cancer Inst. 1994 Aug 3;86(15):1152-8.

PMID:
8028036
31.
33.

Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin.

Lau DH, Durán GE, Sikic BI.

J Natl Cancer Inst. 1992 Oct 21;84(20):1587-92.

PMID:
1404452
34.
35.

Supplemental Content

Loading ...
Support Center